Singapore markets closed
Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,896.38 -798.05 (-1.23%) CMC Crypto 200
1,332.34 -64.19 (-4.60%)
Samsung Biologics Co.,Ltd. (207940.KS)
KSE - KSE Delayed price. Currency in KRW
Add to watchlist
At close: 03:30PM KST
| Previous close | 780,000.00 |
| Open | 779,000.00 |
| Bid | 769,000.00 x 0 |
| Ask | 770,000.00 x 0 |
| Day's range | 769,000.00 - 780,000.00 |
| 52-week range | 668,000.00 - 880,000.00 |
| Volume | |
| Avg. volume | 70,183 |
| Market cap | 55.516T |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 24 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,021,500.00 |
PR NewswireSamsung Biologics Reports First Quarter 2024 Financial Results
Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024.
PR NewswireSamsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC)
Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung's investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.
- Thomson Reuters StreetEvents
Q4 2023 Rapid Micro Biosystems Inc Earnings Call
Q4 2023 Rapid Micro Biosystems Inc Earnings Call
© 2024 Yahoo. All rights reserved.